Test Price
2,800 AED✅ Home Collection Available
ATXN8OS Gene Spinocerebellar Ataxia Type 8 Genetic Test in UAE | 2800 AED | DHA Licensed Laboratory
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation by a DHA-licensed consultant medical geneticist.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
- DHA Facility License: 1143
Test Overview & Methodology
The ATXN8OS gene test detects the specific CTG repeat expansion responsible for autosomal dominant spinocerebellar ataxia type 8 (SCA8), a progressive neurodegenerative disorder affecting coordination and balance. This next-generation sequencing (NGS) assay evaluates both expanded allele size and clinical pathogenicity, delivering actionable genetic information used by neurologists and genetic counsellors across the UAE.
The assay measures CTG repeat expansions in the ATXN8OS gene, providing definitive molecular confirmation for suspected SCA8 cases and enabling accurate genetic counselling for at-risk family members.
Our Test vs. Closest Alternative
| Parameter | Our ATXN8OS NGS Test | Standard Single-Gene PCR |
|---|---|---|
| Precision | 99.9% analytical sensitivity & specificity; NGS detects even low-level mosaicism | Limited resolution; may miss complex expansions or interruptions |
| Method | Next Generation Sequencing (Illumina platform) with repeat-primed PCR verification | Conventional PCR with fragment analysis |
| Turnaround Time | 3 to 4 Weeks | 4 to 6 Weeks (often sent abroad) |
Physician Insight & Safety Protocols
"Understanding your genetic risk profile through the ATXN8OS repeat expansion analysis provides clarity for clinical decision-making. A positive finding must always be interpreted alongside a comprehensive neurological examination and detailed family pedigree. Our team, supervised by Consultant Medical Genetics Lina Osama Zaki Quteineh (DHA Registration ID: 9294403), ensures compassionate post-test counselling to support your next steps."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DNA Labs UAE
Pre-Test Clinical Advisory
Continue all prescribed medications unless explicitly advised otherwise by your treating physician. This genetic test provides diagnostic information and does not replace ongoing clinical management or medication regimens. A mandatory genetic counselling session to document family history and obtain informed consent is required prior to sample collection.
Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Absence of confirmed clinical ataxia symptoms or significant family history; inability to provide informed consent; acute febrile illness within 48 hours prior to home collection; known coagulopathy without physician clearance.
- ER Red Flags (after blood draw): Pronounced dizziness, syncope (fainting), or signs of shock; sudden worsening of ataxia, dysarthria, or breathing difficulty – seek emergency care immediately.
Patient FAQ & Clinical Guidance
1. What sample type is required for the ATXN8OS genetic test and how is it collected?
A: A venous whole blood sample collected in an EDTA tube, a dried blood spot on an FTA card, or previously extracted genomic DNA are all acceptable. Our premium home collection service dispatches a certified phlebotomist to your location between 8 AM and 11 PM, using temperature-controlled cold-chain transport to preserve sample integrity from bedside to laboratory.
2. What preparation is needed before providing a sample for this test?
A: Fasting is not routinely required. However, a pre-test genetic counselling session is mandatory to document your pedigree and obtain informed consent. If providing a dried blood spot, avoid anticoagulant medications such as aspirin for 24 hours prior. Detailed instructions will be provided during your counselling appointment.
3. How should I interpret a positive or negative result for my health?
A: A positive result confirms the presence of a pathogenic ATXN8OS repeat expansion, indicating elevated risk for developing cerebellar atrophy and progressive neurological symptoms. A negative result indicates absence of the specific expansion but does not rule out other ataxia subtypes. Ongoing clinical follow-up with a neurologist remains essential regardless of the outcome.
UAE Regulatory & Data Privacy Adherence
This service complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. All genetic data is processed with encryption, anonymization, and secure storage protocols. Our laboratory holds ISO 9001:2015 certification and is licensed by the Dubai Health Authority (Facility No. 1143).
Clinical & Logistical Metadata
| Test Name | ATXN8OS Gene Spinocerebellar Ataxia Type 8 Genetic Test |
| Price (AED) | 2800 |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA tube), Extracted DNA, or FTA Card |
| Methodology Used | Next-Generation Sequencing (NGS) with repeat-primed PCR verification |
| ICD-10-CM Code | G11.2 |
| LOINC Code | 101370-4 |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians